Immunogen, Inc. (IMGN) Misses Q3 Expectations
Immunogen, Inc. (NASDAQ: IMGN) reported Q3 EPS of ($0.44), $0.17 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $6.9 million versus the consensus estimate of $13.28 million.
For earnings history and earnings-related data on Immunogen, Inc. (IMGN) click here.